# Legend Bio 在體內 CAR-T 治療早期數據公布後股價上漲。

*biotech · news · 2026-06-02 · Seeking Alpha*

## Key points

- Legend Biotech 的 LB2501 是一種針對 B 細胞非霍奇金淋巴瘤的體內 CAR-T 治療。
- LB2501 在早期人體臨床試驗中顯示初步正面結果。
- Legend Biotech 股價在試驗公告後上漲約 26%。
- LB2501 採用直接在體內施用 CAR-T 治療的新穎方法。

Legend Bio rises after early-stage data for in vivo CAR-T therapy Jun 02, 2026, 11:07 AM ETLigand Pharmaceuticals Incorporated (LGND) StockBy : Dulan Lokuwithana, SA News Editor Comment (1) Legend Biotech (LGND) added ~26% in the morning hours on Tuesday after announcing initial results from an early-stage trial for LB2501, its in vivo CAR-T cell therapy targeting B-cell non-Hodgkin lymphoma, the most common form of non-Hodgkin lymphoma. Citing data Newsletters for Every Investor Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities. Subscribe to Newsletters

**Companies:** Legend Biotech, Ligand Pharmaceuticals Incorporated

[Read the full story on Seeking Alpha](https://seekingalpha.com/news/4599842-legend-bio-posts-early-stage-data-car-t-drug)

---

Canonical: https://newsio.io/zh-TW/n/801d3b13-8727-42a7-9a2c-7119a2a0101b/legend-bio-car-t
Summarized by Newsio from Seeking Alpha. https://newsio.io/how-it-works